- Home
- MHUA vs PSTV Comparison
MHUA vs PSTV Comparison
Compare MHUA & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- PSTV
- Stock Information
- Founded
- MHUA 1990
- PSTV 1996
- Country
- MHUA China
- PSTV United States
- Employees
- MHUA N/A
- PSTV N/A
- Industry
- MHUA Medical Specialities
- PSTV Medical/Dental Instruments
- Sector
- MHUA Health Care
- PSTV Health Care
- Exchange
- MHUA Nasdaq
- PSTV Nasdaq
- Market Cap
- MHUA 19.6M
- PSTV 17.0M
- IPO Year
- MHUA 2022
- PSTV N/A
- Fundamental
- Price
- MHUA $0.37
- PSTV $0.59
- Analyst Decision
- MHUA
- PSTV Strong Buy
- Analyst Count
- MHUA 0
- PSTV 3
- Target Price
- MHUA N/A
- PSTV $10.83
- AVG Volume (30 Days)
- MHUA 168.0K
- PSTV 18.9M
- Earning Date
- MHUA 09-19-2025
- PSTV 08-13-2025
- Dividend Yield
- MHUA N/A
- PSTV N/A
- EPS Growth
- MHUA N/A
- PSTV N/A
- EPS
- MHUA 0.40
- PSTV N/A
- Revenue
- MHUA $96,909,642.00
- PSTV $5,206,000.00
- Revenue This Year
- MHUA N/A
- PSTV $8.26
- Revenue Next Year
- MHUA N/A
- PSTV $8.39
- P/E Ratio
- MHUA $0.93
- PSTV N/A
- Revenue Growth
- MHUA N/A
- PSTV N/A
- 52 Week Low
- MHUA $0.25
- PSTV $0.16
- 52 Week High
- MHUA $1.26
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- MHUA 39.91
- PSTV 63.31
- Support Level
- MHUA $0.38
- PSTV $0.45
- Resistance Level
- MHUA $0.41
- PSTV $0.61
- Average True Range (ATR)
- MHUA 0.03
- PSTV 0.07
- MACD
- MHUA -0.01
- PSTV 0.01
- Stochastic Oscillator
- MHUA 9.10
- PSTV 67.95
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).